BCDA
NASDAQBioCardia Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$0.91-0.10 (-9.58%)
01:30 PM06:15 PM
News · 26 weeks47-15%
2025-12-142026-06-07
Mix3590d
- SEC Filings15(43%)
- Other10(29%)
- Insider6(17%)
- Earnings4(11%)
Latest news
25 items- SECBioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - BioCardia, Inc. (0000925741) (Filer)
- PRBioCardia Announces $4.4 Million FinancingNet proceeds anticipated to extend cash runway into first quarter of 2027 beyond expected Japan PMDA submission; if currently outstanding warrants issued in previous financings are exercised in full for cash, it is anticipated that the cash runway would extend well beyond PMDA approval and into first commercial sales. SUNNYVALE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, sold 3,509,604 shares at an average price of $1.279 on Friday, June 5, 2026. No warrants were issued in this capital raise. About BioCardia® BioCardia, Inc., headquartered
- SECBioCardia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - BioCardia, Inc. (0000925741) (Filer)
- PRFDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEFSUNNYVALE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced receipt of FDA minutes from its Q-Sub Meeting with FDA Center for Biologics Evaluation and Research (CBER) on the CardiAMP Cell Therapy System for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF). The meeting minutes from FDA confirm that the ongoing CardiAMP Heart Failure II Trial may support Premarket Approval (PMA) for market clearance. PMA is the most rigorous type of device marketing application required by the agency. It is used to establis
- SECBioCardia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - BioCardia, Inc. (0000925741) (Filer)
- PRBioCardia Announces Japan PMDA Record Of Advice Supports Regulatory Submission For Approval Of CardiAMP Cell Therapy For Ischemic Heart FailureSUNNYVALE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported the Consultation Record from Japan's Pharmaceutical and Medical Device Agency (PMDA) supports submission for regulatory approval of the CardiAMP® cell therapy for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF) based on the Company's three completed clinical trials of this therapy in HFrEF. PMDA's Consultation Record confirms alignment on remaining questions to address before, and as part of the submission, for regulatory approval for ischemic HFr
- INSIDERPresident and CEO Altman Peter bought $1,570 worth of shares (1,700 units at $0.92), increasing direct ownership by 0.58% to 293,266 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- SECBioCardia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - BioCardia, Inc. (0000925741) (Filer)
- PRBioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency– Positive CardiAMP CMI Trial open-label cohort results demonstrated opportunity for locally delivered cell therapy to enhance therapeutic options for patients with severely symptomatic refractory angina and validate continued clinical development – Novel therapeutic approach targets a critically important unmet medical need for patients who have debilitated quality-of-life and have exhausted all available treatment options SUNNYVALE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the oral presentation of the results of the CardiA
- PRBioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company ShowcaseSUNNYVALE, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, will participate virtually in a fireside chat at A.G.P.'s Healthcare Company Showcase. Fireside Chat Details: Time: 11:40 AM ETDate: Wednesday, May 20, 2026 Investors can register for the conference and view the fireside chat here. About BioCardia® BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Comp
- INSIDERPresident and CEO Altman Peter bought $5,244 worth of shares (5,700 units at $0.92), increasing direct ownership by 2% to 291,566 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERPresident and CEO Altman Peter bought $5,202 worth of shares (5,100 units at $1.02), increasing direct ownership by 2% to 285,866 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- SECSEC Form 10-Q filed by BioCardia Inc.10-Q - BioCardia, Inc. (0000925741) (Filer)
- SECBioCardia Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BioCardia, Inc. (0000925741) (Filer)
- PRBioCardia Reports First Quarter 2026 Business Highlights and Financial ResultsSUNNYVALE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter 2026 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2026 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session. Recent Business Highlights CardiAMP® autologous cell therapy in ischemic heart failure of reduced ejectio
- PRBioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the first quarter of 2026 by conference call on Friday, May 15, 2026 at 4:30 PM EDT. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to: https://dpregister.com/sreg/10209272/104069d5d88. Please note that registered participants will receive their dial-in number upon registration. For those who have not registered,
- SECBioCardia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - BioCardia, Inc. (0000925741) (Filer)
- PRBioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance PathwaysSUNNYVALE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the outcome of its Pre-Submission Meeting with FDA on the Helix Transendocardial Delivery Catheter System (Helix). FDA agreed that there are two pathways for Helix marketing clearance and raised no concerns on Helix safety data, device performance, or compatibility with general classes of agents. FDA's preferred route of Helix approval was simultaneous with the approval of the CardiAMP cell therapy system for the treatment of heart failure. FDA also suggested a follow-
- INSIDERPresident and CEO Altman Peter bought $5,550 worth of shares (5,000 units at $1.11), increasing direct ownership by 2% to 280,766 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- SECBioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - BioCardia, Inc. (0000925741) (Filer)
- PRBioCardia Announces Allowance of Japanese Patent on Proprietary Heart3D™ Fusion Imaging Software for Procedure Planning and Realtime Navigation During CardiAMP Cell Therapy ProceduresSUNNYVALE, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the allowance of Japanese Patent, "Target Site Selection, Entry, and Update with Automatic Remote Image Annotation." This patent adds further protection to BioCardia's proprietary Heart3D™ Fusion Imaging (Heart3D) software intended for treatment planning and real-time navigation during CardiAMP Cell Therapy procedures. The allowed Japanese patent has claims on the use of Heart3D fusion imaging configured for transposing a preoperative three-dimensional image obtained by Co
- INSIDERSEC Form 4 filed by Altman Peter4 - BioCardia, Inc. (0000925741) (Issuer)
- SECBioCardia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - BioCardia, Inc. (0000925741) (Filer)
- PRBioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart FailureSUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported a positive outcome in its formal clinical consultation with Japan's Pharmaceutical and Medical Device Agency (PMDA). PMDA has determined that the clinical safety and efficacy evidence for the CardiAMP® Cell Therapy in ischemic heart failure is likely sufficient to support market clearance. Good alignment was achieved in the meeting on the acceptability of the foreign clinical data that has been developed in the United States, the indications for use in patients, the approac
- SECBioCardia Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - BioCardia, Inc. (0000925741) (Filer)
BCDA FAQ
6 questionsWhat does BioCardia Inc. do?
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease. The company is also developing ALLOGENEIC Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery...Where does BCDA stock trade?
BioCardia Inc. (BCDA) is listed on NASDAQ.What sector and industry is BCDA in?
BioCardia Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about BCDA?
BioCardia Inc. has had 1 recent analyst action on file. The most recent action was from HC Wainwright & Co.: Buy with a $900.00 price target on 2021-12-20. Recent price targets cluster around $900.00.What companies are similar to BCDA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare BCDA side-by-side with any of them on Quantisnow.How can I track BCDA on Quantisnow?
Quantisnow aggregates BioCardia Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BCDA to receive live email and push alerts on every new disclosure.